Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract …
L Locati, D Galbiati, G Calareso, S Alfieri, R Granata… - 2018 - ascopubs.org
6086 Background: Systemic chemotherapy and targeted therapies (TT) are almost
ineffective in R/M ACC patients (pts). Sorafenib and axitinib showed some activity, possibly …
ineffective in R/M ACC patients (pts). Sorafenib and axitinib showed some activity, possibly …
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life
LD Locati, D Galbiati, G Calareso, S Alfieri, S Singer… - Cancer, 2020 - Wiley Online Library
Background The treatment of patients with recurrent and/or metastatic (R/M) salivary gland
adenoid cystic carcinoma (ACC) remains an unmet need. Methods Patients with R/M …
adenoid cystic carcinoma (ACC) remains an unmet need. Methods Patients with R/M …
Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma
V Tchekmedyian, EJ Sherman, L Dunn… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant
neoplasm of predominantly salivary gland origin for which effective therapies are lacking …
neoplasm of predominantly salivary gland origin for which effective therapies are lacking …
A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
V Tchekmedyian, EJ Sherman, L Dunn, C Tran… - 2018 - ascopubs.org
6022 Background: Recurrent/metastatic adenoid cystic carcinoma (R/M ACC) is a malignant
neoplasm of salivary gland origin with no standard treatment. The majority of ACCs are …
neoplasm of salivary gland origin with no standard treatment. The majority of ACCs are …
Centralised RECIST assessment and clinical outcomes with lenvatinib monotherapy in recurrent and metastatic adenoid cystic carcinoma
L Feeney, Y Jain, M Beasley, O Donnelly, A Kong… - Cancers, 2021 - mdpi.com
Simple Summary Adenoid cystic carcinoma (ACC) is a rare cancer of the head and neck.
Initial treatment may involve surgery and/or radiotherapy with the aim of removing the cancer …
Initial treatment may involve surgery and/or radiotherapy with the aim of removing the cancer …
A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
M Mohamadpour, EJ Sherman, A Kriplani, JV Fetten… - 2023 - ascopubs.org
6048 Background: Recurrent/metastatic adenoid cystic carcinoma (R/M ACC) is a rare
salivary gland cancer (SGC) without standard treatments. The multitargeted, antiangiogenic …
salivary gland cancer (SGC) without standard treatments. The multitargeted, antiangiogenic …
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid …
6040 Background: ACC is a rare tumor that overexpresses VEGF, primarily affecting salivary
glands. Often indolent, it can progress, with metastases common in the lungs, liver, and …
glands. Often indolent, it can progress, with metastases common in the lungs, liver, and …
A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma …
6020 Background: ACC is a rare tumor that overexpresses VEGF, primarily affecting salivary
glands. Often indolent, it can progress, with metastases common in lungs, liver, and bone …
glands. Often indolent, it can progress, with metastases common in lungs, liver, and bone …
Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.
G Zhu, L Zhang, R Li, S Dou, W Yang, C Zhang - 2018 - ascopubs.org
6026 Background: There is no specific therapy, including targeted agents, has consistently
improved clinical outcomes in recurrent/metastatic adenoid cystic carcinoma of the head and …
improved clinical outcomes in recurrent/metastatic adenoid cystic carcinoma of the head and …
[HTML][HTML] A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in …
NG Chau, SJ Hotte, EX Chen, SF Chin, S Turner… - Annals of oncology, 2012 - Elsevier
Background Vascular endothelial growth factor (VEGF) and c-kit are highly expressed in
adenoid cystic carcinoma (ACC) and associated with biologic aggressiveness. This study …
adenoid cystic carcinoma (ACC) and associated with biologic aggressiveness. This study …